PREVENTING BRIBERY AND CORRUPTION Sample Clauses
The "Preventing Bribery and Corruption" clause establishes a contractual obligation for parties to avoid engaging in any form of bribery or corrupt practices during the course of their business relationship. Typically, this clause requires all parties to comply with relevant anti-bribery laws, implement internal controls, and report any suspected violations. Its core function is to promote ethical conduct, protect the parties from legal liability, and maintain the integrity of the business arrangement by explicitly prohibiting corrupt activities.
POPULAR SAMPLE Copied 2 times
PREVENTING BRIBERY AND CORRUPTION. No making or authorizing of payments or gifts in order to obtain or retain business or to secure an improper advantage. No asking or permitting of third parties to do so. • Reporting of any suspicion of potentially corrupt behaviour.
PREVENTING BRIBERY AND CORRUPTION. No making or authorizing of payments or gifts in order to obtain or retain business or to secure an improper advantage. No asking or permitting of third parties to do so. • Reporting of any suspicion of potentially corrupt behaviour. • Compliance with all applicable laws on bribery and corruption including without limitation, the US Foreign Corrupt Practices Act and the UK Bribery Ad 2010 Schedule 3—Designated Persons For the purpose of Section 5.3.3 and 5.3.4 of the Agreement, • Flexion’s designated person shall initially be […***…]; and • AstraZeneca’s designated person shall be AstraZeneca’s […***…] which at the date of this Agreement is […***…]. The Parties shall duly notify each other of any changes to its respective designated person. ***Confidential Treatment Requested Schedule 4—Description of TrK TrkA is the specific receptor for nerve growth factor (NGF); TrkB is the specific receptor for brain derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-4/5); and TrkC is the specific receptor for neurotrophin-3 (NT-3). Schedule 5—Disclosure Letter Licence Agreement to be made between AstraZeneca AB and Flexion Therapeutics Inc. in respect of the compound […***…] We refer to the licence agreement (“Agreement”) to be entered into today between AstraZeneca AB (“AstraZeneca”) and Flexion Therapeutics Inc (“Flexion”) for the licensing of certain intellectual property rights by AstraZeneca to Flexion. This letter is the Disclosure Letter referred to in the Agreement and constitutes formal disclosure to Flexion for the purposes of the Agreement of the facts and circumstances which are or may be inconsistent with the representations and warranties in Section 12.2 of the Agreement (Additional Representations and Warranties of AstraZeneca) (hereinafter referred to as “Warranties”) or which otherwise give or may give rise to a claim under the Agreement by Flexion in respect of the Warranties. Such facts and circumstances will be deemed to qualify the Warranties accordingly. The disclosures are made against the Warranties as a whole. A disclosure or qualification made by reference to any particular paragraph shall be deemed to be made also in respect of any other paragraph to which the disclosure or qualification may be applicable. The disclosure of any matter or document shall not imply any representation, warranty or undertaking not expressly given in the Agreement nor shall such disclosure be taken as extending the scope of any of the Warranties. By way o...